These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative. Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164 [TBL] [Abstract][Full Text] [Related]
7. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients. Straub N; Beivers A; Lenk E; Aradi D; Sibbing D Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566 [TBL] [Abstract][Full Text] [Related]
9. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome. Tan GM; Lam YY; Yan BP Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998 [TBL] [Abstract][Full Text] [Related]
10. Precatheterization Use of P2Y Badri M; Abdelbaky A; Li S; Chiswell K; Wang TY J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939715 [TBL] [Abstract][Full Text] [Related]
11. Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Aitmokhtar O; Paganelli F; Benamara S; Azaza A; Bonello L; Hamza O; Seddiki S; Benathmane T; Saidane M; Bouzid A; Kara M; Sik A; Azzouz A; Harbi F; Monsuez JJ; Benkhedda S Arch Cardiovasc Dis; 2017 Nov; 110(11):626-633. PubMed ID: 28583820 [TBL] [Abstract][Full Text] [Related]
12. Glycoprotein IIb/IIIa inhibitor use in patients with acute myocardial infarction undergoing PCI: Insights from the TRANSLATE ACS study. Ibrahim H; Kaltenbach LA; Hess CN; Recchia T; Effron MB; Stone GW; Wang TY Catheter Cardiovasc Interv; 2019 Mar; 93(4):E204-E210. PubMed ID: 30244509 [TBL] [Abstract][Full Text] [Related]
13. Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry. Godschalk TC; Byrne RA; Adriaenssens T; Malik N; Feldman LJ; Guagliumi G; Alfonso F; Neumann FJ; Trenk D; Joner M; Schulz C; Steg PG; Goodall AH; Wojdyla R; Dudek D; Wykrzykowska JJ; Hlinomaz O; Zaman AG; Curzen N; Dens J; Sinnaeve P; Desmet W; Gershlick AH; Kastrati A; Massberg S; Ten Berg JM; JACC Cardiovasc Interv; 2017 Dec; 10(24):2548-2556. PubMed ID: 29268884 [TBL] [Abstract][Full Text] [Related]
14. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303 [TBL] [Abstract][Full Text] [Related]
15. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction. Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480 [TBL] [Abstract][Full Text] [Related]
16. P2Y12 inhibitors in acute coronary syndrome: when to give them and when to prolong their use. Grotti S; Bolognese L J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e9-e12. PubMed ID: 29538137 [No Abstract] [Full Text] [Related]
17. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer? Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K; Thromb Haemost; 2015 Jan; 113(1):37-52. PubMed ID: 25231675 [TBL] [Abstract][Full Text] [Related]